Search Results

Leica Biosystems is pleased to announce that its flagship digital pathology system, Aperio GT 450 DX, has received 510(k) clearance from the US Food and Drug Administration.

Aperio Clinical Outcomes, a prominent data focused clinical research organization, appoints Eric Ross as Chief Commercial Officer, as the company adds additional infrastructure to support continued growth.

bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio”) today announced it has signed its first Medicaid outcomes-based agreement for LYFGENIA.

TFF Pharmaceuticals, Inc. today announced that the Company has engaged Outcome Capital as a strategic advisor for the purpose of evaluating potential corporate partnerships and licensing opportunities.

Woolsey Pharmaceuticals, a clinical-stage drug development company, announced that its investigational drug, CIRARA, was well tolerated and exhibited statistically significant reductions in a key biomarker, Neurofilament Light (NfL), in the REAL Amyotrophic Lateral Sclerosis (ALS) study.

Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, and Palantir Technologies Inc.

Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing inhaled therapeutics to treat serious respiratory diseases, today announced positive outcomes from Part 2 of a multi-part Phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of its orally inhaled pan-JAK inhibitor KN-002.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced plans to advance investigational plozasiran into a Phase 3 cardiovascular outcomes trial called CAPITAN.